Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study

Author:

Horsager Jacob1ORCID,Andersen Katrine B1,Knudsen Karoline1,Skjærbæk Casper1,Fedorova Tatyana D1ORCID,Okkels Niels1,Schaeffer Eva2,Bonkat Sarah K2ORCID,Geday Jacob3,Otto Marit45,Sommerauer Michael6,Danielsen Erik H5,Bech Einar7,Kraft Jonas8,Munk Ole L1,Hansen Sandra D9,Pavese Nicola110ORCID,Göder Robert11,Brooks David J110,Berg Daniela2,Borghammer Per1ORCID

Affiliation:

1. Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus, Denmark

2. Department of Neurology, Christian-Albrechts-University Kiel, Kiel, Germany

3. Neurologen, Horsens, Denmark

4. Aarhus University Hospital, Department of Clinical Neurophysiology, Aarhus, Denmark

5. Aarhus University Hospital, Department of Neurology, Aarhus, Denmark

6. University of Cologne, Department of Neurology, Cologne, Germany

7. Neuroklinik-Aarhus, Aarhus, Denmark

8. Neurolog Jonas Kraft, Aarhus, Denmark

9. Neurolog i Odense, Odense, Denmark

10. Institute of Translational and Clinical Neuroscience, Newcastle University, Newcastle, UK

11. Department of Psychiatry and Psychotherapy, Christian-Albrechts-University Kiel, Kiel, Germany

Abstract

Abstract Parkinson’s disease is characterized by the presence of abnormal, intraneuronal α-synuclein aggregates, which may propagate from cell-to-cell in a prion-like manner. However, it remains uncertain where the initial α-synuclein aggregates originate. We have hypothesized that Parkinson’s disease comprises two subtypes. A brain-first (top-down) type, where α-synuclein pathology initially arises in the brain with secondary spreading to the peripheral autonomic nervous system; and a body-first (bottom-up) type, where the pathology originates in the enteric or peripheral autonomic nervous system and then spreads to the brain. We also hypothesized that isolated REM sleep behaviour disorder (iRBD) is a prodromal phenotype for the body-first type. Using multimodal imaging, we tested the hypothesis by quantifying neuronal dysfunction in structures corresponding to Braak stages I, II and III involvement in three distinct patient groups. We included 37 consecutive de novo patients with Parkinson’s disease into this case-control PET study. Patients with Parkinson’s disease were divided into 24 RBD-negative (PDRBD−) and 13 RBD-positive cases (PDRBD+) and a comparator group of 22 iRBD patients. We used 11C-donepezil PET/CT to assess cholinergic (parasympathetic) innervation, 123I-metaiodobenzylguanidine (MIBG) scintigraphy to measure cardiac sympathetic innervation, neuromelanin-sensitive MRI to measure the integrity of locus coeruleus pigmented neurons, and 18F-dihydroxyphenylalanine (FDOPA) PET to assess putaminal dopamine storage capacity. Colon volume and transit times were assessed with CT scans and radiopaque markers. Imaging data from the three groups were interrogated with ANOVA and Kruskal-Wallis tests corrected for multiple comparisons. The PDRBD− and PDRBD+ groups showed similar marked reductions in putaminal FDOPA-specific uptake, whereas two-thirds of iRBD patients had normal scans (P < 10−13, ANOVA). When compared to the PDRBD− patients, the PDRBD+ and iRBD patients showed reduced mean MIBG heart:mediastinum ratios (P < 10−5, ANOVA) and colon 11C-donepezil standard uptake values (P = 0.008, ANOVA). The PDRBD+ group trended towards a reduced mean MRI locus coeruleus: pons ratio compared to PDRBD− (P = 0.07, t-test). In comparison to the other groups, the PDRBD+ group also had enlarged colon volumes (P < 0.001, ANOVA) and delayed colonic transit times (P = 0.01, Kruskal-Wallis). The combined iRBD and PDRBD+ patient data were compatible with a body-first trajectory, characterized by initial loss of cardiac MIBG signal and 11C-colonic donepezil signal followed by loss of putaminal FDOPA uptake. In contrast, the PDRBD− data were compatible with a brain-first trajectory, characterized by primary loss of putaminal FDOPA uptake followed by a secondary loss of cardiac MIBG signal and 11C-donepezil signal. These findings support the existence of brain-first and body-first subtypes of Parkinson’s disease.

Funder

Lundbeck Foundation

Publisher

Oxford University Press (OUP)

Subject

Clinical Neurology

Reference47 articles.

1. Neuropathological basis of nonmotor manifestations of Parkinson’s disease;Adler;Mov Disord,2016

2. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction;Beach;Acta Neuropathol,2009

3. How does Parkinson’s disease begin? Perspectives on neuroanatomical pathways, prions, and histology;Borghammer,2018

4. Brain-first versus gut-first Parkinson’s disease: a hypothesis;Borghammer;J Parkinsons Dis,2019

5. Staging of brain pathology related to sporadic Parkinson’s disease;Braak;Neurobiol Aging,2003

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3